Medicine research news Return to previous page
Article Released Thu-21st-June-2018 09:27 GMT
Contact: Administrator Account Institution: ResearchSEA
 Hitchhiking to Kill

Transport of lipid-conjugated floxuridine by natural serum albumin for delivery to cancer cells.

Image Name
How can elimination of therapeutics from the bloodstream or their early enzymatic degradation be avoided in systemic delivery? Chinese scientists have new developed a method to bind an established cancer therapeutic, floxuridine, with natural serum albumin for its transport and delivery to target cancer cells. In the journal Angewandte Chemie, the authors demonstrate the automated synthesis of a conjugated floxuridine polymer, its successful transport and delivery, and its efficiency in stopping tumor growth.

How can we get a drug to its target? Despite much progress in nanocarrier research, the problem is still persistent, especially in cancer therapy. During transport in the bloodstream, the anticancer drugs may interfere with healthy cells, or they may be degraded by enzymes or eliminated from the body before entering the tumor tissue. Envisaging a natural and safe carrier system, Weihong Tan and colleagues at Hunan University, China, and the University of Florida, USA, chose endogeneous serum albumin as a possible nanotransporter. To ensure binding of the antimetabolite floxuridine to albumin, they had to modify it.

Floxuridine is a fluorinated pyrimidine nucleoside and antimetabolite, which inhibits the enzymes of DNA synthesis. Its oligomer, an oligonucleotide of 10 units, is even more efficient and is actively internalized in the cell. To make it transportable by serum albumin, Prof. Tan and his group decided to endow the oligonucleotide with hydrophobic alkyl chains as a linker. This was necessary because albumin naturally transports lipophilic molecules such as lipids and cholesterol, but not negatively charged oligonucleotides.

The synthesis of the alkyl-chain-conjugated floxuridine oligonucleotide containing 20 units (LFU20) proceeded on a DNA synthesizer. The authors tested the compound for its interaction with serum albumin, cell internalization, transport through the bloodstream in tumor-implanted mice, and tumor proliferation. They observed that although a large fraction of the drug still left the body, a much higher proportion than in the control group accumulated in the tumor. There, the drug was internalized in the cells. The “enhanced permeability and retention effect” directed the accumulation, an effect well established in tumor research. In the cells, the lysosomes take up the drug, and enzymes release the antimetabolic floxuridine structure, the authors note.

The scientists reported that tumor proliferation was halted by the lipid-conjugated compound, whereas the free FU20 drug without lipid anchor could not stop tumor growth. This means that LFU20 appears to “hitchhike” with albumin to find the target cells and accumulate therein. The authors also pointed out that the drug is easily prepared by automated synthesis, and the hydrophobic lipid tail, which ensures the albumin affinity, can be readily incorporated at the 5’-terminus of the oligonucleotide. Hitchhiking with killing potential pays off in drug delivery.

(3099 characters)

About the Author
Dr. Weihong Tan is an adjunct professor at the Biomedical Engineering Department and the Department of Chemistry at the Hunan University, China, and a distinguished professor at the University of Florida. His research areas are understanding the molecular foundation of disease using aptamers and the application of molecular engineering and bio-nanotechnology to create probes with interesting properties and clever designs.

Author: Weihong Tan, Department of Chemistry University of Florida (United States)

Title: Floxuridine Homomeric Oligonucleotides “Hitchhike” with Albumin In Situ for Cancer Chemotherapy

Angewandte Chemie International Edition
Permalink to the original article (link below) – Please use in your news piece to make sure altmetric.com picks it up and a link to your piece is shown on the journal's website.

Copy free of charge. We would appreciate a transcript of your article or a reference to it.
The original article is available from our online pressroom (link below)
Contact: Editorial office: angewandte@wiley-vch.de
To be removed from this list, please e-mail us.

Angewandte Chemie is a journal of the Gesellschaft Deutscher Chemiker (German Chemical Society, GDCh) and is published by Wiley-VCH. It is one of the prime chemistry journals in the world.

Angewandte Chemie International Edition, Postfach 101161, 69451 Weinheim, Germany.

Associated links

Keywords associated to this article:
Create Account...